



## MAYRA ROMINA LOMONACO

License Number: ME137220

Profession	Medical Doctor
License Status	Clear/Active
Year Began Practicing	07/01/2013
License Expiration Date	01/31/2026

## General Information

### Primary Practice Address

MAYRA ROMINA LOMONACO  
6056 BOYNTON BEACH BLVD  
BOYNTON BEACH, FL 33437

### Medicaid

This practitioner DOES participate in the Medicaid program.

### Staff Privileges

This practitioner currently holds staff privileges at the following hospital/medical/health institutions:

Institution Name	City	State
SHANDS HOSPITAL AT THE UNIVERSITY OF FLO	GAINESVILLE	FLORIDA

### Email Address

Please contact at: romilomonaco@yahoo.com

### Other State Licenses

This practitioner has not indicated any additional state licensures.

### Florida Birth-Related Neurological Injury Compensation Association

If you are a Florida Allopathic (MD) or Osteopathic (DO) Physician, you are required to provide proof of payment of the Florida Birth-Related Neurological Injury Compensation Association (NICA) assessment as required by section 766.314, Florida Statutes. Payment of the initial and annual assessment are required of all Florida Allopathic and Osteopathic Physicians who do not qualify for an exemption as set forth in section 766.314(4)(b)4, Florida Statutes.

This practitioner has indicated that he/she has submitted payment of the assessment.

## Education and Training

### Education and Training

Institution Name	Degree Title	Dates of Attendance	Graduation Date
UNIVERSIDAD NACIONAL DEL NORDESTE		2/1/1997 - 1/22/2005	01/22/2005

### Other Health Related Degrees

This practitioner does not hold any additional health related degrees.

### Professional and Postgraduate Training

This practitioner has not completed any graduate medical education.

# Academic Appointments

## Graduate Medical Education

This practitioner has had the responsibility for graduate medical education within the last 10 years.

## Academic Appointments

This practitioner does not currently hold faculty appointments at any medical/health related institutions of higher learning.

# Specialty Certification

## Specialty Certification

This practitioner does not hold any certifications from specialty boards recognized by the Florida board which regulates the profession for which he/she is licensed.

# Financial Responsibility

## Financial Responsibility

I have elected not to carry medical malpractice insurance however, I agree to satisfy any adverse judgments up to the minimum amounts pursuant to s. 458.320(5) (g)1, F. S. I understand that I must either post notice in a sign prominently displayed in my reception area or provide a written statement to any person to whom medical services are being provided that I have decided not to carry medical malpractice insurance. I understand that such a sign or notice must contain the wording specified in s. 458.320(5) (g), F.S.

# Proceedings and Actions

## Proceedings & Actions

### Criminal Offenses

**The criminal history information, if any exists, may be incomplete; federal criminal history information is not available to the public. Information is verified by the Department at the time of initial licensure and renewal.**

This practitioner has indicated that he/she has no criminal offenses required to be published on this profile.

### Medicaid Sanctions and Terminations

This practitioner has not been sanctioned or terminated for cause from the Medicaid program.

### Final Disciplinary Actions Reported by the Department of Health within the last 10 years:

**The information below is self reported by the practitioner.**

### Final disciplinary action taken by a specialty board within the last 10 years:

This practitioner has indicated that he/she has \*NOT\* had any final disciplinary action taken against him/her within the last 10 years by a specialty board.

### Final disciplinary action taken by a licensing agency within the last 10 years:

This practitioner has indicated that he/she has \*NOT\* had any final disciplinary action taken against him/her within the last 10 years by a licensing agency.

### Disciplinary action taken by a health maintenance organization, pre-paid health clinic, nursing home, licensed hospital or ambulatory surgical center within the last 10 years:

This practitioner has indicated that he/she has \*NOT\* had any final disciplinary action taken against him/her within the last 10 years by a health maintenance organization, pre-paid health clinic, nursing home, licensed hospital or ambulatory surgical center.

The following discipline has been reported as required under 456.041(5), F.S. within the previous 10 years.

**Resignation from or non-renewal of medical staff membership or the restriction or revocation of staff privileges within the last 10 years by a health maintenance organization, pre-paid health clinic, nursing home, licensed hospital or ambulatory surgical center in lieu of or in settlement of a pending disciplinary case related to competence or character.**

This practitioner has indicated that he/she has **\*NEVER\*** been asked to or allowed to resign from or had any medical staff privileges restricted or revoked within the last 10 years by a health maintenance organization, pre-paid health clinic, nursing home, licensed hospital or ambulatory surgical center.

**Liability Claims Exceeding \$100,000.00 Within last 10 years.**

Settlement of a claim may occur for a variety of reasons that do not necessarily reflect negatively on the professional competence or conduct of the physician. A payment settlement of a medical malpractice action or claim should not be construed as creating a presumption that medical malpractice has occurred.

**Additional claims information may have been reported to the Department of Financial Services. To check their web site, please click [here](#).**

There have not been any reported liability actions, which are required to be reported under section 456.049, F. S., within the previous 10 years.

**Optional Information**

**Committees/Memberships**

This practitioner has an affiliation with the following committees:

- American Diabetes Association
- Endocrine Society

**Professional or Community Service Awards**

This practitioner has not provided any professional or community service activities, honors, or awards.

**Publications**

This practitioner has authored the following publications in peer-reviewed medical literature within the previous ten years:

Title	Publication	Date
ROLE OF ETHNICITY IN OVERWEIGHT AND OBESE SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)	HEPATOLOGY 2011; 54:837-845	
EFFECT OF ADIPOSE TISSUE INSULIN RESISTANCE ON METABOLIC PARAMETERS AND LIVER HISTOLOGY IN OBESE PATIENTS WITH NAFLD	HEPATOLOGY 2012; 55:1389-1397	
LIMITED VALUE OF PLASMA CYTOKERATIN-18 AS A BIOMARKER FOR NASH AND FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE	J HEPATOL 2014; 60:167-174	
RELATIONSHIP BETWEEN DISEASE SEVERITY, HYPERINSULINEMIA AND IMPAIRED INSULIN CLEARANCE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)	HEPATOLOGY 2014; 59:2178-2187	
THE ROLE OF LIVER FAT AND INSULIN RESISTANCE AS DETERMINANTS OF PLASMA AMINOTRANSFERASE ELEVATION IN NONALCOHOLIC FATTY LIVER DISEASE	HEPATOLOGY 2015; 61:153-160.	
RELATIONSHIP OF VITAMIN D WITH INSULIN RESISTANCE AND DISEASE SEVERITY IN NONALCOHOLIC STEATOHEPATITIS	J HEPATOL 2015; 62:405-411	
CLINICAL VALUE OF ULTRASOUND FOR THE DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE IN OVERWEIGHT AND OBESE PATIENTS	LIVER INT 2015; 35:2139-2146	
HIGH PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NORMAL PLASMA AMINOTRANSFERASE LEVELS	J CLIN ENDOCRINOL METAB 2015; 100:2231-2238	
RELATIONSHIP OF VITAMIN D WITH INSULIN RESISTANCE AND DISEASE SEVERITY IN NON-ALCOHOLIC STEATOHEPATITIS	J HEPATOL 2015;62:405-411	
HEPATIC STEATOSIS AND INSULIN RESISTANCE, BUT NOT STEATOHEPATITIS, PROMOTE ATHEROGENIC DYSLIPIDEMIA IN NAFLD	J CLIN ENDOCRINOL METAB 2016;101:644- 652	

Title	Publication	Date
PLASMA THYROID HORMONE CONCENTRATION IS ASSOCIATED WITH HEPATIC TRIGLYCERIDE CONTENT IN PATIENTS WITH TYPE 2 DIABETES	J INVESTIG MED 2016, 64:63-68	
METABOLIC IMPACT OF NONALCOHOLIC STEATOHEPATITIS (NASH) IN OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)	DIABETES CARE 2016, 39:632-638	
LONG-TERM PIOGLITAZONE TREATMENT FOR PATIENTS WITH NASH AND PREDIABETES OR T2DM: A RANDOMIZED CONTROLLED TRIAL	ANN INTERN MED 2016, 165:305-315	
METABOLIC AND HISTOLOGICAL IMPLICATIONS OF INTRAHEPATIC TRIGLYCERIDE CONTENT IN NONALCOHOLIC FATTY LIVER DISEASE	HEPATOLOGY 2017, 65:1132-1144	
LIVER SAFETY OF STATINS IN PREDIABETES OR T2DM AND NONALCOHOLIC STEATOHEPATITIS: POST HOC ANALYSIS OF A RANDOMIZED TRIAL	J CLIN ENDOCRINOL METAB 2017, 102:2950-2961	
RESPONSE TO PIOGLITAZONE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS WITH VS WITHOUT TYPE 2 DIABETES	CLIN GASTROENTEROL HEPATOL 2018, 16:558-566	
EFFECT OF PIOGLITAZONE ON BONE MINERAL DENSITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: A 36-MONTH CLINICAL TRIAL	J. DIABETES 2019, 11:223-231	
ROLE OF VITAMIN E FOR NONALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL	DIABETES CARE 2019, 42:1481-1488	
CHANGE IN HEPATIC FAT CONTENT MEASURED BY MRI DOES NOT PREDICT TREATMENT-INDUCED HISTOLOGICAL IMPROVEMENT OF STEATOHEPATITIS	J HEPATOL 2020, 72:401-410	
ADVANCED LIVER FIBROSIS IS COMMON IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FOLLOWED IN THE OUTPATIENT SETTING: THE NEED FOR SYSTEMATIC SCREENING	DIABETES CARE 2021, 44:399-406	
INTACT FASTING INSULIN DEFINES NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITHOUT DIABETES.	J CLIN ENDOCRINOL METAB 2021; DOI: 10.1210/CLINEM/DGAB417.	
AN ENDOCRINE PERSPECTIVE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)	THER ADV ENDOCRINOL METAB 2011; 2:211-225	
THE CHALLENGE OF MANAGING DYSLIPIDEMIA IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE	CLIN LIPIDOL 2012; 7:471-481	
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN DIABETES: DISTRACTION OR IMPENDING DISASTER?	EVIDENCE-BASED MANAGEMENT OF DIABETES. VORA J, BUSE J, EDS. TFM PUBLISHING LTD: SHREWSBURY, UK, 2012; CHAPTER 21: 383-404	
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): CURRENT ISSUES AND NOVEL TREATMENT APPROACHES	DRUGS 2013; 73:1-14	
THE FUTURE OF THIAZOLIDINEDIONE THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS	CURR DIABETES REP 2013; 13:329-341	
TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH)	INTERNATIONAL TEXTBOOK OF DIABETES MELLITUS. DEFRONZO RA, FERRANNINI E, ZIMMET P, ALBERTI GK. FOURTH ED. OXFORD, UK: JOHN WILEY & SONS, LTD; 2015; CHAPTER 20: 292-305	

### Professional Web Page

This practitioner has not provided any professional web page information.

### Languages Other Than English

This practitioner has indicated that the following languages other than English are used to communicate with patients, or that a translation service is available for patients, at his/her primary place of practice.

SPANISH

**Other Affiliations**

This practitioner has not provided any national, state, local, county, or professional affiliations.